Results 221 to 230 of about 98,962 (385)
Building a Better Innovation System: Combining Facially Neutral Patent Standards withTherapeutics Regulation [PDF]
, 2008 Rai, Arti K.
core +1 more source
Control of biopharmaceutical properties of uricase by conjugation with dextran derivatives.
, 1989 Yoshinobu Takakura +4 more
openalex +2 more sources
Characteristics of the late-stage biopharmaceutical pipeline [PDF]
, 2004 Paul P Nagle +2 more
openalex +1 more source
Yeasts as Biopharmaceutical Production Platforms
Frontiers in Fungal Biology, 2021 N. Kulagina +5 more
semanticscholar +1 more source
Management of patients with heart failure at high risk of hyperkalaemia: The CARE‐HK in HF registry
European Journal of Heart Failure, EarlyView.Primary results of the CARE‐HK in HF registry. ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; CI, confidence interval; eGFR, estimated glomerular filtration rate; HF, heart failure; HK, hyperkalaemia; HR, hazard ratio; MRA, mineralocorticoid receptor antagonist; RASi,
Stephen J. Greene +24 more
wiley +1 more source
Research and development financing models for new biopharmaceuticals in the United States. [PDF]
Health Aff SchKang SY +4 more
europepmc +1 more source
Production and employment impacts of new technologies: analysis for biotechnology [PDF]
Biotechnology is often regarded as a key technology with high potential for far-reaching social, environmental and economic impacts. Among others, the development and diffusion of biotechnology may have considerable economic effects on production and ...
Wydra, Sven
core
European Journal of Heart Failure, EarlyView.Global patterns of polypharmacy after acute heart failure hospitalization. GDMT, guideline‐directed medical therapy; HF, heart failure. Aims Polypharmacy, defined as the concurrent use of ≥5 medications, is prevalent among older adults with heart failure (HF).
Wan Ting Tay +19 more
wiley +1 more source